MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents

Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Info

Publication number
MA56513A
MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
Authority
MA
Morocco
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
MA056513A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Kerren Kalai Swinger
Melissa Marie Vasbinder
Timothy J N Wigle
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MA56513A publication Critical patent/MA56513A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA056513A 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie MA56513A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19

Publications (1)

Publication Number Publication Date
MA56513A true MA56513A (fr) 2022-04-27

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056513A MA56513A (fr) 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Country Status (11)

Country Link
US (1) US20220388985A1 (fr)
EP (1) EP3986887A1 (fr)
JP (2) JP2022537349A (fr)
KR (1) KR20220024098A (fr)
CN (2) CN120398840A (fr)
AU (1) AU2020296063B2 (fr)
BR (1) BR112021025645A2 (fr)
CA (1) CA3142002A1 (fr)
MA (1) MA56513A (fr)
SG (1) SG11202112980TA (fr)
WO (1) WO2020257416A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102835667B1 (ko) 2017-12-21 2025-07-21 애브비 바이오테크놀로지 리미티드 Parp14 억제제로서의 퀴나졸리논
JP2024502467A (ja) * 2021-01-08 2024-01-19 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ニンボリドアナログ及びその使用方法
WO2022165118A1 (fr) * 2021-01-29 2022-08-04 Ribon Therapeutics, Inc. Méthodes de traitement de maladies inflammatoires
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
EP4562007A1 (fr) 2022-07-29 2025-06-04 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
TW202417435A (zh) 2022-07-29 2024-05-01 美商律幫治療股份有限公司 用於治療之parp14之靶向蛋白質降解
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (fr) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 Dérivé de quinazolinone et son utilisation médicale
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666530C2 (ru) * 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
US9505749B2 (en) * 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
UA119870C2 (uk) * 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
AU2017367872B2 (en) * 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
EP3580212A4 (fr) * 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. Régulation de récepteurs d'antigènes chimériques
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
KR102835667B1 (ko) * 2017-12-21 2025-07-21 애브비 바이오테크놀로지 리미티드 Parp14 억제제로서의 퀴나졸리논

Also Published As

Publication number Publication date
BR112021025645A2 (pt) 2022-02-01
JP2025102917A (ja) 2025-07-08
EP3986887A1 (fr) 2022-04-27
CN114206853A (zh) 2022-03-18
AU2020296063B2 (en) 2026-01-29
AU2020296063A1 (en) 2021-12-23
KR20220024098A (ko) 2022-03-03
WO2020257416A1 (fr) 2020-12-24
JP2022537349A (ja) 2022-08-25
SG11202112980TA (en) 2021-12-30
US20220388985A1 (en) 2022-12-08
CA3142002A1 (fr) 2020-12-24
CN120398840A (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
MA56513A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
IL286462A (en) Protein tyrosine phosphatase inhibitors
EP3710002A4 (fr) Agents de dégradation et dégrons pour dégradation protéique ciblée
HUE062404T2 (hu) Protein tirozin foszfatáz inhibitorok
IL289534A (en) Parp1 inhibitors
EP3897631A4 (fr) Dégradation ciblée de protéines
HRP20220269T8 (hr) Heterociklilamino-supstituirani triazoli kao modulatori rho-povezane protein kinaze
EP3565846A4 (fr) Agents thérapeutiques protéiques pour le traitement de cellules sénescentes
EP3952914A4 (fr) Procédés et compositions pour une dégradation de protéine ciblée
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
IL260222A (en) Bromodomain and extra-terminal protein inhibitor combination therapy
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
DK3532059T3 (da) Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
EP3886912A4 (fr) Dendrimère pour thérapie et imagerie
EA201791937A1 (ru) Противовоспалительные полипептиды
EP4013440A4 (fr) Peptides thérapeutiques
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
MA71624A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
MA55467A (fr) Utilisations thérapeutiques de dulaglutide
IL288090A (en) Expression of antigen-binding proteins in the nervous system
IL288237A (en) Combination therapy
EP4039328A4 (fr) Agent soulageant la dysurie